Vasomotor symptoms (VMS) during the menopause transition (MT) are associated with an increased risk for type 2 diabetes (T2D), according to a research letter published online Oct. 31 in JAMA ...
Up to 80% of women experience VMS during menopause, with symptoms lasting a median of 7.4 years. VMS symptoms are often moderate to severe, impacting quality of life significantly. Racial and ...
The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Objective: To update and expand The North American Menopause Society’s evidence-based position on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of ...
The purpose of this study was to evaluate the pharmacokinetics of intranasal hydromorphone hydrochloride (HCl) in patients with vasomotor rhinitis. Methods: Ten patients completed the randomised ...